Investor experience in biotechnology
Requires Subscription or Fee PDF

Keywords

venture capital
finance
experience
seed
start-up
policy

Abstract

Biotechnology is viewed as an industry that combines scientific innovation, entrepreneurial management and experienced investment to drive innovation, primarily in biomedicine. This paper examines the third of these assumed preconditions. We find that the majority of investors in biotechnology companies over the last decade by number or by value have not been experienced, and that the majority of investors in biotechnology companies have invested in less than three such companies in the decade, suggesting that they have very limited experience of biotechnology. 13% of investment syndicates contain no investors who have made more than three biotechnology investments. Investor inexperience is disproportionately high in Seed and Series A rounds, but has little correlation with amount invested. Investor inexperience is found in all categories of investors and all territories, although US investors tend to have greater experience than those outside North America. The banking crisis of 2008-11 has not materially changed this. We suggest that the conventional image of biotechnology investment as the careful selection and nurturing of young companies by experienced investors is incomplete. This has implications for candidate investor selection by entrepreneurs, and for government support of biotechnology by supporting investors or investment mechanisms. 

https://doi.org/10.5912/jcb742
Requires Subscription or Fee PDF

References

Lee, D.P. and M.D. Dibner, The rise of venture capital and biotechnology in the US and Europe. Nature Biotechnology, 2005. 23(6): p. 672 - 676. http://www.nature.com/nbt/journal/v23/n6/abs/nbt0605-672.html

Bradford, T.C., Evolving symbiosis - venture capital and biotechnology. Nature Biotechnology, 2003. 21(9): p. 983 - 984. http://www.nature.com/nbt/journal/v21/n9/full/nbt0903-983.html

Browning, J., The incredible shrinking venture capital. Nature 2009. 460: p. 459. http://www.nature.com/nature/journal/v460/n7254/full/460459a.html

Huggett, B., Biotech's wellspring: a survey of the health of the private sector. Nat Biotech, 2012. 30(5): p. 395-400. http://www.nature.com/nbt/journal/v30/n5/full/nbt.2209.html

Festel, G. and C. Rammer, Importance of venture capital investors for the industrial biotechnology industry. Journal of Commercial Biotechnology, 2015. 21(2): p. 31 - 42. http://commercialbiotechnology.com/index.php/jcb/article/view/685

PriceWaterHouseCoopers LLC, Biotech funding surges. Q4 2014 Life Sciences Report. 2015, PriceWaterHouse Coopers LLC. p. http://www.pwcmoneytree.com/Reports/FullArchive/Life%20Sciences_2014-4.pdf

Carroll, J., Dominant VC NEA gathers $3B megafund, preps for a wave of biotech rounds, in Fierce Biotech. 2015, Questex Media Group LLC: Newton, MA, USA. p. http://www.fiercebiotech.com/story/dominant-vc-nea-gathers-3b-preps-another-wave-biotech-rounds/2015-04-15.

Huggett, B., Biotech's wellspring[mdash]a survey of the health of the private sector in 2014. Nat Biotech, 2015. 33(5): p. 470-477. http://www.nature.com/nbt/journal/v33/n5/full/nbt.3218.html

Philippidis, A., Cost, Competitive Pressures Could Push Biotechs to More M&A Deals, in Genetic Engineering News. 2015, Mary Anne Liebert Inc: New York, NY, USA. p. http://www.genengnews.com/gen-news-highlights/ey-cost-competitive-pressures-could-push-biotechs-to-more-m/81251385/.

Bains, W., S. Wooder, and D.R.M. Guzman, Funding biotech start-ups in a post-VC world. Journal of Commercial Biotechnology, 2014. 20(1): p. 10 - 27. http://logos-press.com/journals/index.php/jcb/article/view/628

Ford, D. and B. Nelsen, The view beyond venture capital. Nat Biotech, 2014. 32(1): p. 15-23. http://www.nature.com/nbt/journal/v32/n1/full/nbt.2780.html

Ernst & Young LLP, Globalizing venture capital: Global venture capital insights and trends report 2012, Ernst & Young LLP: London, UK.

Huggett, B. and R. Lähteenmaki, Public biotech 2011 - by the numbers. Nature Biotechnology, 2012. 30: p. 751 - 757. http://www.nature.com/nbt/journal/v30/n8/full/nbt.2320.html

Cambridge Associates LLC, Cambridge Associates LLC U. S. Venture Capital Index and selected benchmark statistics. 2011, National Venture Capital Association: Boston, MA. http://www.endowmentwm.com/wp-content/uploads/2013/05/2012-Q4-NVCA-Benchmark-Book.pdf

Booth, B.I. and B. Salehizadeh, In defence of life science venture investing. Nature Biotechnology, 2011. 29(7): p. 579 - 583. http://www.nature.com/nbt/journal/v29/n7/abs/nbt.1908.html

Bains, W., Venture Capital and the European Biotechnology Industry. 2008, Basingstoke, UK: Palgrave Macmillan. http://www.williambains.co.uk/vcbio/

Mulcahy, D., B. Weeks, and H.S. Bradley, We have met the enemy ... and he is us. Lessons from twenty years of the Kauffman Foundation's investments in Venture Capital Funds and the triumph of hope over experience. 2012, Ewing Marion Kauffmann Foundation: Kansas City, MO. http://www.kauffman.org/~/media/kauffman_org/research%20reports%20and%20covers/2012/05/we_have_met_the_enemy_and_he_is_us.pdf

Sahlman, W.A., The structure and governance of venture-capital organizations., in Venture Capital, M. Wright and K. Robbie, Editors. 1997, Dartmouth: Aldershot, UK. p. 3 - 51. [No web site]

Gompers, P. and J. Lerner, The venture capital revolution. Journal of Economic Perspectives, 2001. 15(2): p. 145 - 168. http://www.jstor.org/stable/2696596

Gompers, P.A. and J. Lerner, The Venture Capital Cycle: 2nd edition. 2004, Cambridge, MA: MIT Press. [No web site]

Gorman, M. and W.A. Sahlman, What do venture capitalists do? Journal of Business Venturing, 1989. 4: p. 231 - 248. http://www.sciencedirect.com/science/article/pii/0883902689900141

Sapienza, H.J., When do venture capitalists add value? Journal of Business Venturing, 1992. 7(1): p. 9-27. http://www.sciencedirect.com/science/article/pii/088390269290032M

MacMillan, I.C., D.M. Kulow, and R. Khoylian, Venture capitalists' involvement in their investments: extent and performance, in Venture Capital, M. Wright and K. Robbie, Editors. 1997, Dartmouth: Aldershot, UK. p. 246 - 265. http://www.sciencedirect.com/science/article/pii/0883902689900323

Anon, Biotech hamstrung by investment strategies. Chemistry and Industry, 2004. 2004(1): p. 5. [No web site]

Bains, W., What you give is what you get: investment in European biotechnology. Journal of Commercial Biotechnology, 2006. 12(4): p. 274 - 283. http://logos-press.com/journals/index.php/jcb/article/view/177

Riquelmo, H. and J. Watson, Do venture capitalists' implicit theories on new business success/failure have empirical validity? International Small Business Journal, 2002. 20(4): p. 395 - 420. http://isb.sagepub.com/content/20/4/395.short

Dimov, D.P. and D.A. Shepherd, Human capital theory and venture capital firms: exploring 'home runs' and 'strike outs'. Journal of Business Venturing, 2005. 20(1): p. 1 - 21. http://www.sciencedirect.com/science/article/pii/S0883902604000035

Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Reconsidering the venture capitalists' “value added†proposition: An interorganizational learning perspective. Journal of Business Venturing, 2004. 19(6): p. 787-807. http://www.sciencedirect.com/science/article/pii/S0883902603001058

Cumming, D., G. Fleming, and J.-A. Suchard, Venture capitalist value-added activities, fundraising and drawdowns. Journal of Banking and Finance, 2005. 29(2): p. 295 - 331. http://www.sciencedirect.com/science/article/pii/S0378426604000378

Lutz, E., et al., Importance of spatial proximity between venture capital investors and investees in Germany. Journal of Business Research, 2013. 66(11): p. 2346-2354. http://www.sciencedirect.com/science/article/pii/S0148296312001245

Clarysse, B., A. Bobelyn, and I.d.P. Aguirre, Learning from own and others’ previous experience: the contribution of the venture capital firm to the likelihood of a portfolio company’s trade sale. Small Business Economics, 2013. 40(3): p. 575 - 590. http://link.springer.com/article/10.1007/s11187-011-9381-0

Taylor, J., Implications of Financing Your Biotechnology Start-up, in Nature / TradeSecrets. 2011, Nature Publishing Group: London, UK. [No web site]

Springham, D.G., V. Moses, and R.E. Cape, Biotechnology - The Science and the Business. 1999, Washington, DC, USA: CRC Press. https://www.crcpress.com/Biotechnology---The-Science-and-the-Business/Springham-Moses-Cape/p/book/9789057024078

Kolchinsky, P., The entrepreneur's guide to a biotech start-up. 2004, Boston, MA, USA: Evelexa. http://uccai.ctsi.ucla.edu/file-storage/view/docs/EGBS4_Kolchinsky.pdf

De Rubertis, F., R. Fleck, and W. Lanthaler, Six secrets to success—how to build a sustainable biotech business. Nat Biotech, 2009. 27(7). http://www.nature.com/nbt/journal/v27/n7/abs/bioe.2009.5.html

Brown, J., Venture capital and firm performance over the long-run: Evidence from high-tech IPOs in the United States. Journal of Entrepreneurial Finance, 2005. 10(3): p. 1-33. [no web site]

Davila, A., G. Foster, and M. Gupta, Venture capital financing and the growth of startup firms. Journal of Business Venturing, 2003. 18(6): p. 689-708. http://www.sciencedirect.com/science/article/pii/S0883902602001271

Croce, A., J. Martí, and S. Murtinu, The impact of venture capital on the productivity growth of European entrepreneurial firms: ‘Screening’ or ‘value added’ effect? Journal of Business Venturing, 2013. 28(4): p. 489-510. http://www.sciencedirect.com/science/article/pii/S0883902612000705

Baum, J.A.C. and B.S. Silverman, Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups. Journal of Business Venturing, 2004. 19(3): p. 411-436. http://www.sciencedirect.com/science/article/pii/S0883902603000387

Ernst & Young LLP, Beyond Borders 2013. . 2013, Ernst and Young LLP: London, UK. http://www.ey.com/Publication/vwLUAssets/Beyond_borders/$FILE/Beyond_borders.pdf

Gorman, M. and W.A. Sahlman, What do venture capitalists do? Journal of Business Venturing, 1989. 4(4): p. 231-248. http://www.sciencedirect.com/science/article/pii/0883902689900141

Janney, J.J. and T.B. Folta, Moderating effects of investor experience on the signaling value of private equity placements. Journal of Business Venturing, 2006. 21(1): p. 27-44. http://www.sciencedirect.com/science/article/pii/S0883902605000443

Zider, B., How venture capital works. Harvard Business Review, 1998. 1998(December). [No Web Site]

Lerner, J., The Syndication of Venture Capital Investments. Financial Management, 1994. 23(3): p. 16-27. http://www.jstor.org/stable/3665618

Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Signalling in venture capitalist-new venture team funding decisions: does it indicate long-term venture outcomes? International Small Business Journal, 2005. 29(1): p. 1 - 12. http://onlinelibrary.wiley.com/doi/10.1111/j.1540-6520.2005.00066.x/full

Hsu, D.H., What do entrepreneurs pay for venture capital affiliation? Journal of Finance, 2004. 59(4): 1805 - 1844. http://onlinelibrary.wiley.com/doi/10.1111/j.1540-6261.2004.00680.x/full.

Booth, B.L., This time may be different. Nat Biotech, 2016. 34(1): p. 25-30. http://www.nature.com/nbt/journal/v34/n1/abs/nbt.3452.html

Crawford, M., Biotech Market Changing Rapidly. A shakeout looms as investment wanes and cash reserves dip; delays, competition affect all but the fittest biotech ventures. Science, 1986. 231(4733): p. 12-14. http://science.sciencemag.org/content/231/4733/12

Ernst, D. and D. Mackie, Fighting the Financing Frenzy: What Next for Biotechnology Companies? Nat Biotech, 1988. 6(5): p. 495-501. http://www.nature.com/nbt/journal/v6/n5/full/nbt0588-495.html

Howell, M., M. Trull, and M.D. Dibner, The rise of European venture capital for biotechnology. Nat Biotech, 2003. 21(11): p. 1287-1291. http://www.nature.com/nbt/journal/v21/n11/full/nbt1103-1287.html

Martino, P., The micro VC shakeout, TechCrunch, Editor. 2015, TechCrunch. http://techcrunch.com/2015/04/26/the-microvc-shakeout/

Lee, D.P. and M.D. Dibner, The rise of venture capital and biotechnology in the US and Europe. Nat Biotech, 2005. 23(6): p. 672-676. http://www.nature.com/nbt/journal/v23/n6/full/nbt0605-672.html

Fleming, J.J., The Decline Of Venture Capital Investment In Early-Stage Life Sciences Poses A Challenge To Continued Innovation. Health Affairs, 2015. 34(2): p. 271-276. http://content.healthaffairs.org/content/34/2/271.short

Dembosky, A., US venture capital investment declines, in Financial Times (London). 2012, FT: London. [no cuurent Web Page]

Lash, A. and T. Salemi, Venture capital survey paints bleak portrait, in The Pink Sheet. 2012, Elsevier: Bridgewater, NJ. p. 17 - 19. https://www.pharmamedtechbi.com/publications/the-pink-sheet/74/40/venture-capital-survey-paints-bleak-portrait

Ghalbouni, J. and D. Rouzies, The VC Shakeout. Harvard Business Review, 2010. 2010(7): p. https://hbr.org/2010/07/the-vc-shakeout. https://hbr.org/2010/07/the-vc-shakeout/ar/1

Tam, P.-W., Venture-Capital Firms Caught in a Shakeout, in Wall Street Journal. 2010, Wall Street Journal: New York, NY, USA. http://www.wsj.com/articles/SB10001424052748703915204575104221092909884http://www.wsj.com/articles/SB10001424052748703915204575104221092909884.

Waters, R., Investment fears in venture capital shake-out, in Financial Times. 2009, FT: London, UK. p. http://www.ft.com/cms/s/2/c78a2fc0-da8b-11dd-8c28-000077b07658.html#axzz41e9iZrlG.

Nanda, R. and M. Rhodes-Kropf, Investment cycles and startup innovation. Journal of Financial Economics, 2013. 110(2): p. 403-418. http://www.sciencedirect.com/science/article/pii/S0304405X13001967

Groysberg, B., Chasing Stars: The Myth of Talent and the Portability of Performance 2011, Princeton, NJ: Princeton University Press. http://press.princeton.edu/titles/9128.html

Thakor, A.V., Comment on Trester. Journal of Banking and Finance, 1998. 22(6 - 8): p. 700 - 701. [No Web Page]

Birch, D., The job creation process. 1979, M.I.T. programme on neighborhood and regional change: Cambridge, MA. [No Web Page]

Lambert, R., Lambert Review of Business-University Collaboration: final report. 2003, HMSO: London, UK. http://eua.be/eua/jsp/en/upload/lambert_review_final_450.1151581102387.pdf

UKTI, Bioscience UK. 2008, UK Trade and Investment: London. [No Web Page]

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.